Viyash Scientific Limited (NSE: VIYASH | BSE: 512529)
Source: Viyash Scientific Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)
📋 Quick Facts: Viyash Scientific Snapshot & Key Takeaways
- Core Business & Market Position: Viyash Scientific Limited (formerly known as Sequent Scientific Limited) is an integrated global pharmaceutical platform delivering Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage formulations across both human health and animal health segments, supported by contract development and manufacturing organization (CDMO) services.
- FY26 Financial Trajectory: Consolidated Revenue from Operations expanded 13.75% year-on-year to reach ₹3,420.31 Crores in FY26 (up from ₹3,006.84 Crores in FY25), driven by robust 18% growth in formulations to ₹1,865.70 Crores and 8% expansion in APIs to ₹1,490.60 Crores. EBITDA surged 59.66% to ₹702.50 Crores, while Profit After Tax (PAT) expanded multi-fold to ₹224.65 Crores.
- Key Growth Catalyst: Successful composite scheme of amalgamation merging erstwhile Viyash Life Sciences Private Limited and its operating subsidiaries into Sequent Scientific Limited (subsequently renamed Viyash Scientific Limited), creating an integrated “One R&D” scientific engine with over 250 scientists (20+ PhDs), 16 global manufacturing units (10 USFDA approved), and backward-integrated oncology and complex chemistry capabilities.
- Primary Balance Sheet / Operational Watchpoint: Substantial deleveraging achieved with Net Debt to EBITDA dropping from 1.03x to 0.24x (Net Debt reduced from ₹451.10 Crores to ₹166.10 Crores). Key operational watchpoints include integration execution across global commercial networks, regulatory compliance across 10 USFDA-approved sites, and raw material cost inflation in complex chemistry intermediates.
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Viyash Scientific Limited |
| Corporate Identity Number (CIN) | L99999TS1985PLC196357 |
| ISIN | INE807F01027 |
| Stock Exchange Listing | BSE Limited (Scrip Code: 512529) | National Stock Exchange of India Limited (Symbol: VIYASH) |
| Date of Incorporation / Founding Year | 1985 (Originally incorporated as Visistha Trades; renamed Sequent Scientific Limited; renamed Viyash Scientific Limited w.e.f. January 8, 2026) |
| Founders / Key Figures | Dr. Haribabu Bodepudi (Founder of Viyash Lifesciences) |
| Registered Office | 3rd Floor, Srivalli’s Corporate, Plot No. 290, Road No. 6, Sy. No. 33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India – 500033 |
| Telephone & Investor Email | +91 40 23635000 / +91 22 41114777 | investorrelations@viyash.com |
| Chairman | Dr. Kamal Sharma (Non-Executive Chairman & Independent Director) |
| Managing Director & Group CEO | Dr. Haribabu Bodepudi |
| Executive Director & CEO – Animal Health | Mr. Rajaram Narayanan |
| Whole-time Director | Mr. Srinivas Vasireddy |
| Chief Financial Officer (CFO) | Mr. Ramakant Singani (w.e.f. January 1, 2026) |
| Company Secretary & Compliance Officer | Ms. Yoshita Vora |
| Promoter & Holding Group | Carlyle Group (CA Harbor Investments & CA Hull Investments holding 61.31% combined) |
| Industry / Sector Classification | Pharmaceuticals (NIC Code: 21001) |
| Total Workforce / Employees | 2,568 Permanent Employees + 1,563 Workers (Total Workforce: 4,131 personnel; Permanent employee turnover rate: 16.48%) |
| Manufacturing Plants Count | 16 Manufacturing Facilities globally (10 API Plants in India, 6 Formulation Plants across Spain, Turkey, Brazil, India, and USA; 10 USFDA approved) |
| Credit Ratings & Rating Agency | India Ratings & Research: Long-Term Bank Facilities upgraded to IND AA- (Stable), Short-Term Bank Facilities upgraded to IND A1+ | ICRA: Working Capital Facilities assigned [ICRA] AA- (Stable) |
| Statutory Auditors | M/s SRBC & CO LLP, Chartered Accountants |
| Secretarial Auditors | M/s BMP & Co. LLP, Practicing Company Secretaries |
| Cost Auditors | M/s Joshi Apte & Associates, Practicing Cost Accountants |
| Registrar & Share Transfer Agent (RTA) | KFin Technologies Limited (Selenium Tower B, Plot 31 & 32, Nanakramguda, Serilingampally, Hyderabad – 500032) |
🏢 The Corporate Identity: Viyash Scientific Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Viyash Scientific Limited operates an integrated global pharmaceutical engine that spans Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage formulations across human health, animal health, and custom contract development and manufacturing organization (CDMO) verticals. The organization serves pharmaceutical innovators, generic manufacturers, and veterinary healthcare providers across more than 150 countries through direct commercial operations, strategic local presences, and distribution partnerships.
The core value proposition of the company relies on complete backward integration across its core product pipeline, with over 85% of key human and animal health formulation products integrated in-house for APIs and intermediates. By pairing process chemistry capabilities with advanced multi-scale reactor manufacturing and regulatory certification across tier-one agencies (including USFDA, EU GMP, WHO GMP, PMDA Japan, TGA Australia, ANVISA Brazil, and COFEPRIS Mexico), Viyash Scientific delivers regulatory compliance, supply chain reliability, and cost-efficient generic and specialty solutions.
The Founders, Promoters & Their Legacy
The foundation of the combined platform traces back to Dr. Haribabu Bodepudi, a scientific entrepreneur who established Viyash Lifesciences Private Limited in February 2019. Under his leadership, Viyash executed a rapid acquisition and expansion strategy, acquiring API and formulation assets from Mylan in Visakhapatnam and Mumbai, Vindhya Pharma, Vandana Life Sciences, Symed Labs, Appcure Labs, and USFDA-approved generic formulations manufacturer Appco Pharma LLC in the United States.
The promoter backing of Viyash Scientific is anchored by global private equity leader Carlyle Group, through its investment entities CA Harbor Investments and CA Hull Investments. Following the composite scheme of amalgamation sanctioned by the Hon’ble NCLT Hyderabad Bench in November 2025, CA Hull Investments was added as a promoter, bringing total Carlyle Group promoter shareholding to 61.31% (CA Hull Investments holding 31.17% and CA Harbor Investments holding 30.14%). The promoter group provides strategic capital allocation, global corporate governance oversight, and institutional sponsorship.
The Journey: Corporate History & Key Milestones
The history of the corporate entity combines the heritage of Sequent Scientific Limited and the rapid inorganic platform scale of Viyash Lifesciences:
- 1985–2009 (Evolution of Sequent): Originating as Visistha Trades, the business rebranded to SeQuent Scientific Limited, establishing a dedicated pharmaceutical and animal health corporate identity.
- 2014–2019 (Global Veterinary Expansion): Created “Alivira” as a dedicated global animal health brand, building India’s only USFDA-approved veterinary API plant in Visakhapatnam, and executing cross-border acquisitions across Europe (Spain, Sweden, Benelux), Brazil, Turkey, and Latin America.
- 2019–2021 (Creation and Scale of Viyash): Dr. Haribabu Bodepudi founded Viyash Lifesciences in February 2019. Accelerated scale through acquisition of Mylan’s API and formulation plants in Visakhapatnam and Mumbai, supported by strategic investment from Carlyle Group, followed by acquisitions of Symed Labs and Appco Pharma LLC in New Jersey, USA.
- 2022–2024 (Specialization and Portfolio Integration): Viyash expanded its scientific talent pool to over 200 scientists, filed over 175 patents, and established dedicated high-potency API (HPAPI) and cytotoxic processing blocks. Sequent Scientific concurrently scaled its animal health presence across Europe and Latin America under Alivira.
- FY2025–26 (The Amalgamation & Rebranding): Hon’ble NCLT Hyderabad Bench sanctioned the Composite Scheme of Amalgamation on November 18, 2025 (effective December 16, 2025), merging Viyash Life Sciences Private Limited and its operating subsidiaries into Sequent Scientific Limited. The merged entity formally changed its name to Viyash Scientific Limited on January 8, 2026.
The Corporate Umbrella & Group Structure
Viyash Scientific Limited serves as the operating holding entity of the merged group. As of March 31, 2026, the company maintains 19 subsidiaries (14 wholly owned), operating an integrated manufacturing and distribution architecture across India, Ireland, Spain, Brazil, Turkey, Germany, Sweden, Belgium, the United Kingdom, Italy, Mexico, and the United States.
⚙️ The Business Engine: Viyash Scientific Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Viyash Scientific operates primarily in a single reportable primary business segment under Ind AS 108 — Pharmaceuticals — comprising four integrated operational verticals:
- Human Health Formulations: Delivers finished dosage forms across regulated and emerging markets, emphasizing niche complex generics, iron compounds, and an integrated oncology portfolio.
- Animal Health Formulations: Marketed globally under the Alivira brand, providing therapeutic and nutritional veterinary solutions for farm animals (cattle, poultry) and companion animals (canine, feline).
- Active Pharmaceutical Ingredients (APIs): Commercializes 60+ human APIs and 33+ animal health APIs globally, backed by batch-size flexibility ranging from 1 kg to 1,000 kg across 10 manufacturing units in India.
- Contract Development & Manufacturing Organization (CDMO): Partners with global originators and specialty generic pharma companies for lifecycle management, chiral chemistry, nitrosamine risk mitigation, and cytotoxic handling.
| Business Vertical / Sales Category | FY 2025-26 Revenue (₹ in Crores) | FY 2024-25 Revenue (₹ in Crores) | % Share of FY26 Revenue | Latest YoY (%) |
|---|---|---|---|---|
| Formulations (Finished Dosage) | 1,865.70 | 1,582.80 | 54.55% | +17.87% |
| Europe Formulations | 668.20 | 561.40 | 19.54% | +19.02% |
| Emerging Markets Formulations | 630.50 | 514.20 | 18.43% | +22.62% |
| USA Formulations | 426.60 | 391.60 | 12.47% | +8.94% |
| India Formulations | 140.50 | 115.50 | 4.11% | +21.65% |
| Active Pharmaceutical Ingredients (APIs) | 1,490.60 | 1,374.70 | 43.58% | +8.43% |
| Other Operating / Scrap Sales | 42.30 | 37.20 | 1.24% | +13.71% |
| Total Global Sales | 3,398.70 | 2,994.60 | 99.37% | +13.49% |
| One-off Adjustments | -5.60 | -7.40 | -0.16% | -24.32% |
| Hyperinflation & Claim Adjustments (Ind AS 29) | 27.30 | 19.60 | 0.80% | +39.29% |
| Reported Revenue from Operations | 3,420.31 | 3,006.84 | 100.00% | +13.75% |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
The company’s commercialized API portfolio comprises 60+ human APIs and 33+ veterinary APIs, with a pipeline of 63+ human API molecules and 24 animal health API molecules under active development. In human formulations, Viyash commercializes 30+ finished dosage products across 7 therapeutic categories, with 24+ dosage forms under active development. The CDMO division manages 15 lifecycle projects for originators and 28 specialty generic co-investment projects.
Top commercial API products disclosed in BRSR Section A (accounting for major revenue contributions) include:
- Linezolid (Human API – Antibiotic): Generated 14.49% of total turnover in FY26 (NIC Code 21001).
- Albendazole (Animal Health API – Anthelmintic): Generated 14.25% of total turnover in FY26.
- Triclabendazole (Animal Health API – Anthelmintic): Generated 5.19% of total turnover in FY26.
- Tapentadol HCl (Human API – Analgesic): Generated 4.76% of total turnover in FY26.
- Hydroxyzine HCl (Human API – Antihistamine): Generated 4.46% of total turnover in FY26.
- Levocetirizine (Human API – Antihistamine): Generated 4.24% of total turnover in FY26.
- Other Products & Formulations: Contributed the remaining 52.61% of total turnover.
In accordance with Ind AS 108 customer concentration disclosures, no single customer accounts for 10% or more of total group revenue during FY26 or FY25, reflecting a diversified global customer base across 250+ B2B clients.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Alivira | Animal Health Formulations & APIs | Global flagship animal healthcare umbrella brand serving livestock and companion animals across 100+ countries. |
| Tulathromycin | Animal Health Formulations (Injectables) | Advanced macrolide antibiotic launched in Brazil and Mexico for bovine and swine respiratory disease management. |
| Udaan 2.0 | India Animal Health (Cattle Field Operations) | Domestic field expansion platform adding 40 cattle field representatives across regional Indian livestock markets. |
| Boehringer Ingelheim Partnership Portfolio | Companion Animal Health (India) | Exclusive domestic distribution arrangement covering canine/feline vaccines and parasiticides (2/3rd market coverage). |
| Linezolid API Block | Human Health API (Antibiotic) | AMRIA-certified global supply platform with BSI Kitemark certification for sustainable antibiotic manufacturing. |
| Iron Complex & Cytotoxic HPAPI Platforms | Human Health CDMO & Specialty Generics | Specialized high-containment technology platforms for innovator lifecycle management and cytotoxic oncology APIs. |
Mapping the Domestic & Global Reach (India vs. Exports)
Viyash Scientific maintains a multi-geography commercial footprint, distributing products across 28 Indian States, 8 Union Territories, and 90+ international countries. Export revenues contributed 43.03% (₹1,471.76 Crores) to total company turnover in FY26.
| Geographical Market Destination | FY 2025-26 Revenue (₹ in Crores) | FY 2024-25 Revenue (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| India (Domestic Market) | 906.83 | 823.73 | +10.09% |
| United States of America (USA) | 488.25 | 428.70 | +13.89% |
| Spain | 365.64 | 280.61 | +30.30% |
| Rest of the World (Emerging Markets, LatAm, Europe, Turkey) | 1,659.59 | 1,473.80 | +12.61% |
| Total Segment Revenue | 3,420.31 | 3,006.84 | +13.75% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The group operates 16 manufacturing facilities globally (11 in India, 5 international) and 11 administrative offices. Ten manufacturing plants hold USFDA approval:
- Mahad, Raigad, Maharashtra (API Unit): 39 KL reactor capacity; USFDA, EU GMP, WHO GMP, PMDA Japan, TGA Australia approved (API / HPAPI focus).
- Anakapalli / Parawada, Andhra Pradesh (API Unit II): 290 KL reactor capacity; USFDA, EU GMP, WHO GMP approved (API / HPAPI focus).
- Sangareddy / Domadugu, Telangana (API Unit III): 80 KL reactor capacity; USFDA, EU GMP, WHO GMP approved.
- Nalgonda / Pittampally, Telangana (API Unit IV): 314 KL reactor capacity; USFDA, EU GMP, WHO GMP approved.
- Jeedimetla, Telangana (API Unit V): 137 KL reactor capacity; USFDA, EU GMP, WHO GMP, COFEPRIS, ANVISA approved.
- Yadadri Bhuvanagiri / Mandollagudem, Telangana (API Unit VI): 490 KL reactor capacity; USFDA, WHO GMP, ANVISA approved (APIs & Advanced Intermediates).
- Yadadri Bhuvanagiri / Koyyalagudem, Telangana (API Unit VII): 266 KL reactor capacity; USFDA approved (Advanced Intermediates).
- Sangareddy / Bollaram, Telangana (API Unit VIII): 412 KL reactor capacity; USFDA approved (Advanced Intermediates).
- MIDC Taloja, Raigad, Maharashtra (Animal API Unit): 80 KL reactor capacity; EU GMP, COFEPRIS Mexico approved.
- Visakhapatnam SEZ, Andhra Pradesh (Alivira Animal API Unit): 290 KL reactor capacity; USFDA, EU GMP, WHO Geneva approved.
- Barcelona, Spain (Formulation Plant): Dedicated beta-lactam powder block and nutritional lines; EU GMP, Turkish GMP approved.
- Ankara / Polatli, Turkey (Formulation Plant): Beta-lactam, non-beta lactam, and hormone lines; EU GMP, Turkish GMP approved.
- Campinas, Sao Paulo, Brazil (Formulation Plant): Powders and premixes; MAPA Brazil approved.
- Minas Gerais / Uberlandia, Brazil (Formulation Plant): Premixes, tablets, pastes, suspensions, solutions; MAPA Brazil approved.
- MIDC Ambernath, Thane, Maharashtra (Formulation Plant): Oral solutions, suspensions, powders, premixes; GMP India, Uganda, Ethiopia, Kenya approved.
- Piscataway, New Jersey, USA (Appco Pharma Formulation Plant): High-speed solid/liquid oral compression, fluid bed processing, lyophilization, fill finish; USFDA approved.
- R&D Engine (“One R&D”): Integrated R&D infrastructure spanning Jeedimetla (Hyderabad), Ankara University (Turkey), and Visakhapatnam, employing 250+ scientists (20+ PhDs), operating 13 chemical labs, 20 ICH-compliant analytical labs, 64 fume hoods, process safety labs (MIE/MIT, ARC, DSC), and holding 175+ filed patents (55+ granted).
📊 The Financial Health: Viyash Scientific Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Revenue from Operations | 3,420.31 | 3,006.84 | 2,680.70 | +13.75% |
| EBITDA (Adjusted for ESOP) | 702.50 | 440.00 | 252.90 | +59.66% |
| EBITDA Margin (%) | 20.54% | 14.63% | 9.43% | – |
| Profit After Tax (PAT) | 224.65 | 15.77 | -38.10 | +1324.54% |
| Net Debt | 166.10 | 451.10 | 551.20 | -63.18% |
| Net Debt to EBITDA (x) | 0.24x | 1.03x | 2.18x | -76.70% |
| Cash Flow from Operations (CFO) | 322.91 | 344.80 | 140.30 | -6.35% |
| Gross Profit Margin (%) | 54.30% | 51.09% | 49.00% | – |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Statement of Profit & Loss Line Item | FY 2025-26 (₹ in Crores) | FY 2024-25 (Restated) (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 3,420.31 | 3,006.84 | +13.75% |
| Other Income | 43.55 | 32.89 | +32.41% |
| Total Income | 3,463.86 | 3,039.73 | +13.95% | Expenses |
| Cost of Materials Consumed | 1,376.93 | 1,238.47 | +11.18% |
| Purchases of Stock-in-Trade | 250.59 | 236.77 | +5.84% |
| Changes in Inventories of FG, WIP & Stock-in-Trade | -64.79 | -5.05 | +1182.97% |
| Employee Benefits Expense | 565.50 | 551.97 | +2.45% |
| Finance Costs | 69.21 | 86.37 | -19.87% |
| Depreciation and Amortisation Expenses | 233.64 | 238.71 | -2.12% |
| Other Expenses | 637.85 | 600.68 | +6.19% |
| Net Monetary Gain / (Loss) on Hyperinflation Economy | 1.70 | -2.93 | N/M |
| EBITDA (Calculated: PBT + Finance Costs + Depr – Other Income) | 608.33 | 304.00 | +100.11% |
| Total Expenses | 3,070.63 | 2,944.99 | +4.27% |
| Profit Before Exceptional Items & Tax | 393.23 | 94.74 | +315.06% |
| Exceptional Items | -44.21 | -81.56 | -45.79% |
| Profit Before Tax (PBT) | 349.03 | 13.18 | +2548.18% | Tax Expense / (Credit) |
| Current Tax | 63.15 | 76.52 | -17.47% |
| Deferred Tax | 61.22 | -79.16 | N/M |
| Adjustment of Tax Pertaining to Earlier Periods | 0.00 | 0.05 | -100.00% |
| Total Tax Expenses / (Credits) | 124.37 | -2.59 | N/M |
| Profit After Tax (PAT) | 224.65 | 15.77 | +1324.54% |
| Attributable to Owners of the Company | 177.29 | 23.22 | +663.52% |
| Attributable to Non-Controlling Interest | 47.37 | -7.45 | N/M |
| Other Comprehensive Income (OCI) (Net of Tax) | 106.90 | 15.03 | +611.24% |
| Total Comprehensive Income for the Year | 331.55 | 30.80 | +976.46% |
| Basic Earnings Per Share (₹ per Share, Face Value ₹2) | 4.09 | 0.54 | +657.41% |
| Diluted Earnings Per Share (₹ per Share, Face Value ₹2) | 4.01 | 0.53 | +656.60% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Balance Sheet Line Item | FY 2025-26 (₹ in Crores) | FY 2024-25 (Restated) (₹ in Crores) | Latest YoY (%) | ASSETS: Non-Current Assets |
|---|---|---|---|
| Property, Plant and Equipment (PPE) | 1,063.41 | 1,033.20 | +2.92% |
| Right-of-Use Assets (ROU) | 74.49 | 65.77 | +13.26% |
| Capital Work-in-Progress (CWIP) | 68.73 | 42.84 | +60.43% |
| Goodwill | 868.72 | 796.08 | +9.12% |
| Other Intangible Assets | 96.32 | 208.13 | -53.72% |
| Intangible Assets Under Development | 1.73 | 0.56 | +208.93% |
| Non-Current Investments | 0.02 | 0.02 | 0.00% |
| Other Non-Current Financial Assets | 22.16 | 20.53 | +7.94% |
| Deferred Tax Assets (Net) | 83.37 | 112.44 | -25.85% |
| Non-Current Income Tax Assets (Net) | 14.03 | 18.60 | -24.57% |
| Other Non-Current Assets | 80.86 | 22.76 | +255.27% |
| Total Non-Current Assets | 2,373.84 | 2,320.93 | +2.28% | ASSETS: Current Assets |
| Inventories | 803.20 | 682.23 | +17.73% |
| Current Investments | 0.05 | 0.07 | -28.57% |
| Trade Receivables | 1,045.23 | 806.47 | +29.61% |
| Cash and Cash Equivalents | 255.76 | 140.30 | +82.30% |
| Bank Balances Other Than Above | 13.95 | 16.90 | -17.46% |
| Loans (Current) | 0.12 | 0.21 | -42.86% |
| Other Current Financial Assets | 1.97 | 9.84 | -79.98% |
| Current Income Tax Assets (Net) | 4.74 | 0.25 | +1796.00% |
| Other Current Assets | 129.53 | 126.52 | +2.38% |
| Total Current Assets | 2,254.55 | 1,782.79 | +26.46% |
| Assets Held for Sale | 0.00 | 28.55 | -100.00% |
| TOTAL ASSETS | 4,628.39 | 4,132.27 | +12.01% | EQUITY AND LIABILITIES: Equity |
| Equity Share Capital | 87.37 | 50.06 | +74.53% |
| Other Equity | 2,823.69 | 2,381.53 | +18.57% |
| Equity Attributable to Owners of the Company | 2,911.06 | 2,431.59 | +19.72% |
| Non-Controlling Interest (NCI) | 203.67 | 133.35 | +52.73% |
| Total Equity (Net Worth) | 3,114.73 | 2,564.94 | +21.43% | LIABILITIES: Non-Current Liabilities |
| Non-Current Borrowings | 302.10 | 352.91 | -14.40% |
| Non-Current Lease Liabilities | 38.44 | 32.34 | +18.86% |
| Other Non-Current Financial Liabilities | 1.08 | 1.08 | 0.00% |
| Non-Current Provisions | 40.32 | 32.85 | +22.74% |
| Deferred Tax Liabilities (Net) | 32.77 | 4.34 | +655.07% |
| Other Non-Current Liabilities | 153.05 | 128.70 | +18.92% |
| Total Non-Current Liabilities | 567.76 | 552.22 | +2.81% | LIABILITIES: Current Liabilities |
| Current Borrowings | 133.72 | 255.44 | -47.65% |
| Current Lease Liabilities | 15.50 | 13.61 | +13.89% |
| Trade Payables | 597.27 | 489.33 | +22.06% |
| Other Current Financial Liabilities | 89.94 | 145.51 | -38.19% |
| Current Provisions | 15.71 | 12.92 | +21.59% |
| Current Tax Liabilities (Net) | 24.06 | 22.26 | +8.09% |
| Other Current Liabilities | 69.70 | 76.04 | -8.34% |
| Total Current Liabilities | 945.90 | 1,015.11 | -6.82% |
| Total Liabilities (Excluding Equity) | 1,513.66 | 1,567.33 | -3.42% |
| TOTAL EQUITY AND LIABILITIES | 4,628.39 | 4,132.27 | +12.01% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
| Statutory Ratio | FY 2025-26 | FY 2024-25 | YoY Variance (%) | Management Explanation for Significant Variance (>25%) |
|---|---|---|---|---|
| Debtors Turnover Ratio (Days) | 102 days | 94 days | 8.51% | Maintained within normal working capital limits following geographic portfolio expansion. |
| Inventory Turnover Ratio (Days) | 79 days | 80 days | -1.25% | Stable inventory management across raw material and finished stock blocks. |
| Interest Coverage Ratio (x) | 8.15x | 4.60x | 77.17% | Significantly improved due to operating EBITDA expansion and reduction in overall debt finance costs. |
| Current Ratio (x) | 2.40x | 1.80x | 33.33% | Enhanced liquidity profile driven by cash generation and deleveraging of short-term borrowings. |
| Debt-Equity Ratio (x) | 0.06x | 0.19x | -68.42% | Substantial deleveraging resulting from debt repayments and increase in equity net worth post-merger. |
| Operating Margin Ratio (%) | 19.00% | 13.00% | 46.15% | Operating leverage driven by backward integration of APIs and product mix shift to complex generics. |
| Net Profit Margin (%) | 7.00% | 1.00% | 600.00% | Sharp expansion in PAT due to core operational profitability and lower finance charges. |
| Return on Net Worth (RONW) (%) | 7.90% | 0.70% | 1,028.57% | Step change in net earnings post-amalgamation operational integration. |
| Net Debt to EBITDA (x) | 0.24x | 1.03x | -76.70% | Significant deleveraging, with Net Debt dropping to ₹166.10 Crores against ₹702.50 Crores EBITDA. |
Cash Flow: Tracking the Money Movement
| Consolidated Cash Flow Summary | FY 2025-26 (₹ in Crores) | FY 2024-25 (Restated) (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities | 322.91 | 344.80 | -6.35% |
| Purchase of Property, Plant & Equipment / CWIP / Intangibles (CapEx) | 134.72 | 108.06 | +24.67% |
| Proceeds from Sale of Fixed Assets / Assets Held for Sale | 10.17% | 2.09% | – |
| Redemption / (Investment) in Bank Fixed Deposits & Mutual Funds (Net) | 3.92 | 20.50 | -80.88% |
| Interest Received | 9.77 | 6.52 | +49.85% |
| Transactions with Non-Controlling Interests | 0.00 | -390.70 | -100.00% |
| Net Cash Generated / (Used in) Investing Activities | -84.12 | -447.22 | -81.19% |
| Proceeds from Issue of Equity Shares / Options / Share Warrants | 10.17% | 2.09% | – |
| Proceeds / (Repayment) of Long-Term & Short-Term Borrowings (Net) | 10.17% | 2.09% | – |
| Payment of Lease Liabilities | -13.57 | -17.54 | -22.63% |
| Interest & Borrowing Costs Paid | -69.02 | -77.43 | -10.86% |
| Dividend Paid to Non-Controlling Interests | -4.91 | -1.85 | +165.41% |
| Net Cash Generated / (Used in) Financing Activities | -123.33 | 87.04 | N/M |
| Net Increase / (Decrease) in Cash and Cash Equivalents | 115.46 | -15.38 | N/M |
| Cash and Cash Equivalents at Beginning of the Year | 140.30 | 156.18 | -10.17% |
| Effect of Exchange Rate Differences on Cash Balances | 0.00 | -0.50 | -100.00% |
| Cash and Cash Equivalents at End of the Year | 255.76 | 140.30 | +82.30% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
In FY26, Viyash Scientific deployed ₹134.72 Crores in total capital expenditure (CapEx) to expand manufacturing capacity, erect new specialized HPAPI/cytotoxic lines, and build a dedicated injectable R&D facility at Ankara University in Turkey. Capital Work-in-Progress (CWIP) as of March 31, 2026, stood at ₹68.73 Crores, with ₹61.34 Crores representing active projects aged under 1 year.
Research and Development (R&D) expenditure for FY26 totaled ₹43.48 Crores (representing 1.27% of total revenue), supporting process optimization, process safety assessments, patent filings, and pipeline scale-up under “One R&D”. Under Section 134(3)(m) disclosures, Total Foreign Exchange Earned was ₹787.95 Crores (primarily from export sales), while Total Foreign Exchange Used was ₹209.21 Crores, generating net foreign exchange earnings of ₹578.74 Crores.
👥 Power & Control: Viyash Scientific Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Dr. Kamal Sharma | Non-Executive Chairman & Independent Director | 00209430 | Independent Director |
| Dr. Haribabu Bodepudi | Managing Director & Group CEO | 01119687 | Executive Director (KMP) |
| Mr. Rajaram Narayanan | Whole-time Director & CEO – Animal Health | 02977405 | Executive Director (KMP) |
| Mr. Srinivas Vasireddy | Whole-time Director | 09771153 | Executive Director (KMP) |
| Mr. Milind Sarwate | Independent Director | 00109854 | Independent Director |
| Ms. Revati Kasture | Independent Director | 07558973 | Independent Director |
| Mr. Anuj Poddar | Non-Executive Director | 01908009 | Non-Executive Non-Independent |
| Mr. Amit Jain | Non-Executive Director (w.e.f. April 22, 2026) | 06917608 | Non-Executive Non-Independent |
| Mr. Abhiroop Jayanthi | Non-Executive Director (w.e.f. April 22, 2026) | 10354445 | Non-Executive Non-Independent |
| Mr. Ramakant Singani | Chief Financial Officer (w.e.f. January 1, 2026) | – | Key Managerial Personnel |
| Ms. Yoshita Vora | Company Secretary & Compliance Officer | – | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
| Shareholder Category | Number of Shares Held | % of Total Issued Equity Shares |
|---|---|---|
| Promoters & Promoter Group (CA Hull & CA Harbor Investments) | 26,78,40,334 | 61.31% |
| Mutual Funds (Domestic Institutional Investors) | 2,81,51,632 | 6.44% |
| Alternative Investment Funds (AIFs) | 67,36,934 | 1.54% |
| Foreign Portfolio Investors (FPIs / Foreign Corporate) | 1,28,50,145 | 2.94% |
| Resident Individuals | 8,28,63,216 | 18.96% |
| Bodies Corporate | 1,43,16,577 | 3.28% |
| Hindu Undivided Family (HUF) | 21,69,603 | 0.50% |
| NRIs (Repatriable & Non-Repatriable) | 65,17,774 | 1.49% |
| Directors & Relatives | 1,39,67,099 | 3.20% |
| Employees & Employee Benefit Trust | 11,92,902 | 0.27% |
| IEPF & Others (Foreign Nationals / Clearing Members) | 2,44,594 | 0.07% |
| Total Equity Share Capital (Face Value ₹2) | 43,68,50,810 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Name of Subsidiary / Operating Entity | Country of Incorporation | % Ownership Interest | FY26 Turnover (₹ in Crores) | FY26 Profit / (Loss) After Tax (₹ in Crores) |
|---|---|---|---|---|
| Alivira Animal Health Limited (India) | India | 100.00% | 449.45 | 4.04 |
| Alivira Animal Health Limited (Ireland) | Ireland | 100.00% | 41.63 | 29.75 |
| Provet Veteriner Urunleri San. Ve Tic. A.S. | Turkey | 100.00% | 189.00 | 12.62 |
| Topkim Ilac Premiks San. Ve Tic. A.S. | Turkey | 100.00% | 126.97 | 23.60 |
| Alivira NV | Belgium | 100.00% | 184.82 | 2.57 |
| N-Vet AB | Sweden | 100.00% | 11.86 | 1.13 |
| Alivira Saude Animal Brasil Participacoes LTDA | Brazil | 100.00% | 18.29 | |
| Alivira Saude Animal Ltda. | Brazil | 100.00% | 202.53 | 1.95 |
| Expeden Distribuidora Productos Vet Ltda | Brazil | 100.00% | 148.19 | 28.86 |
| Vila Vina Participacions, S.L. | Spain | 60.00% | 538.00 | 12.57 |
| Laboratorios Karizoo, S.A. | Spain | 60.00% | 54.69 | 27.18 |
| Laboratorios Karizoo Mexico, S.A. de C.V. | Mexico | 60.00% | 38.56 | 1.75 |
| Phytotherapic Solutions S.L. | Spain | 60.00% | 8.24 | 7.35 |
| Bremer Pharma GmbH | Germany | 100.00% | 17.77 | |
| Alivira Italia S.R.L | Italy | 100.00% | 3.00 | |
| Alivira Animal Health USA LLC | USA | 100.00% | 0.00 | |
| Appco Pharma LLC | USA | 60.00% | 426.66 | 88.02 |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
Credit ratings assigned to Viyash Scientific reflect significant balance sheet strengthening following the merger. India Ratings & Research (Fitch Group) upgraded the company’s long-term credit rating from IND A (Positive) to IND AA- (Stable), while short-term bank facilities were upgraded to IND A1+. ICRA Ratings assigned a long-term rating of [ICRA] AA- (Stable) to fund-based working capital facilities.
Working capital and term loan facilities are syndicated across leading commercial banks, including IDFC First Bank, Barclays Bank PLC, Bank Sinopac, HDFC Bank, Kotak Mahindra Bank, and Banco Sabadell. Contingent liabilities not provided for in the balance sheet total ₹26.69 Crores (comprising ₹24.50 Crores in indirect tax disputes and ₹2.19 Crores in direct tax matters). Corporate guarantees issued to lenders on behalf of subsidiaries total ₹577.50 Crores.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
- Complete Backward Integration (>85% In-House APIs): Secures supply chain continuity, protects gross margins (54.30% in FY26), and allows rapid commercial conversion across complex generic formulations.
- Global Regulatory Compliance Footprint: 16 manufacturing sites with 10 USFDA approvals, EU GMP, PMDA, and ANVISA certifications, establishing high regulatory entry barriers against non-compliant API suppliers.
- “One R&D” Scientific Engine: Consolidated talent pool of 250+ scientists, process safety containment infrastructure, and 175+ patents filed globally, supporting HPAPIs, cytotoxic handling, and complex iron compounds.
- Dual Health Platform Diversity: Well-balanced income distribution across Human Health (APIs, Formulations, CDMO) and Animal Health (Alivira farm/companion animal products across 100+ countries).
What Could Go Wrong? Key Challenges & Business Risks
- Regulatory & Quality Audit Risks: Operations across 10 USFDA-approved facilities require continuous audit readiness. Any regulatory warning letters or import alerts could disrupt export sales.
- Raw Material Cost & Intermediate Volatility: Price fluctuations in key chemical starting materials (KSMs) and energy-sensitive input commodities can pressure processing margins.
- Foreign Exchange Rate Sensitivity: Significant international revenues across Euros, Turkish Lira, US Dollars, and Brazilian Reais expose earnings to currency volatility, mitigated via natural hedging and forward contracts.
- Companion Animal Genericization Speed: Slower-than-projected generic penetration in companion animal pharmaceuticals (<15% generic penetration globally) could delay target growth timelines.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
The strategic agenda for FY27 focuses on commercializing the integrated oncology formulation pipeline, expanding European companion animal field presence (Spain, Benelux, Italy, Sweden), scaling the Boehringer Ingelheim domestic companion animal partnership in India, and deepening high-value innovator CDMO projects. With a deleveraged balance sheet (Net Debt/EBITDA of 0.24x), Viyash Scientific plans to evaluate selective inorganic acquisitions in companion animal health alongside organic product launches.
The Verdict: Strategic Outlook & Conclusion
The integration of Viyash Lifesciences and Sequent Scientific into Viyash Scientific Limited marks the establishment of a premier global pharmaceutical platform. Supported by a robust financial foundation (₹3,420.31 Crores revenue, ₹702.50 Crores EBITDA, and low net debt of ₹166.10 Crores), Carlyle Group promoter backing, and an integrated R&D infrastructure, Viyash Scientific is well-positioned to capitalize on structural genericization tailwinds across human and animal health worldwide.
Frequently Asked Questions (FAQs) About Viyash Scientific
Q1: What does Viyash Scientific Limited manufacture and what are its core brands?
Viyash Scientific Limited manufactures Active Pharmaceutical Ingredients (APIs), advanced intermediates, finished dosage formulations, and provides CDMO services across human and animal health. Its key commercial brand is Alivira for global animal health products, alongside specialized generic formulations in oncology, antibiotics (Linezolid), and anthelmintics (Albendazole).
Q2: What were Viyash Scientific’s revenue and profit figures in FY 2025-26?
In FY 2025-26, Viyash Scientific reported Consolidated Revenue from Operations of ₹3,420.31 Crores (up 13.75% YoY from ₹3,006.84 Crores in FY25), EBITDA of ₹702.50 Crores (up 59.66%), and Profit After Tax (PAT) of ₹224.65 Crores.
Q3: Who are the promoters and Managing Director of Viyash Scientific?
The promoter group is global private equity firm Carlyle Group (holding 61.31% combined through CA Hull Investments and CA Harbor Investments). Dr. Haribabu Bodepudi serves as Managing Director & Group CEO, with Mr. Rajaram Narayanan serving as Whole-time Director & CEO – Animal Health, and Dr. Kamal Sharma serving as Non-Executive Chairman.
Q4: Where are Viyash Scientific’s manufacturing facilities located?
Viyash Scientific operates 16 manufacturing plants globally, including 10 API plants in India (Maharashtra, Telangana, Andhra Pradesh) and 6 formulation plants across Spain (Barcelona), Turkey (Ankara), Brazil (Campinas, Minas Gerais), India (Ambernath), and the United States (Piscataway, New Jersey). Ten plants hold USFDA approval.
Q5: What is Viyash Scientific’s financial debt profile and credit rating?
Viyash Scientific maintains a strong balance sheet with total Net Debt of ₹166.10 Crores as of March 31, 2026, resulting in a Net Debt to EBITDA ratio of 0.24x. India Ratings & Research upgraded its credit rating to IND AA- (Stable) for long-term bank facilities and IND A1+ for short-term facilities.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.viyash.com